Back to All Events

World Economic Forum - Davos 2019 w/ Ken Mulvany


Ken Mulvany, Founder and Executive Chairman of BenevolentAI will participate in the World Economic Forum taking place in Davos.


In 2018 BenevolentAI was named a Technology Pioneer by the World Economic Forum and participated to the World Economic Forum Annual Meeting of the New Champions, held in Tianjin, China where we discussed how using AI can help unlock the world’s most complex operating system - the human body

BenevolentAI is now heading to Davos to participate in the World Economic Forum 2019, where we will be helping to shape and to contribute towards the Forum’s initiatives, aiming to positively transform society and industry.


CNBC: The Future of Healthcare

CNBC’s Elizabeth Schulze hosts a fireside chat with our Founder, Ken Mulvany, to take a look at what BenevolentAI is doing to disrupt the pharma industry.

Wednesday 23 January | 3pm - 3.30pm CET

Location: The Sanctuary, Scalettastrasse 1, 7270 Davos Platz


WEF Panel: The future of the European Union

This is a WEF event, chaired by Jonas Prising, Chairman and CEO of ManpowerGroup with opening remarks form Martina Larkin, Head of Regional Agenda, Europe and Eurasia WEF. It is a session in the annual meeting of the Europe Regional Business Council who convene to discuss and shape business policy in Europe. Our Founder, Ken Mulvany, will be contributing to the topic 'Technology as a driving force for growth and competitiveness in Europe’.

Thursday 24 January | 0730 - 0900

Location: Central Sporthotel, Bundnerstube


Reach out

Our team will be present throughout Davos event. If you’d like to meet with us, please do reach out.


Ken's Biography

Ken+Mulvany+World+Economic+Forum

Serial entrepreneur, investor and healthcare and technology veteran with more than 20 years of business leadership experience. He is currently a director of BenevolentAI, a technology company he founded, which is developing and using Artificial Intelligence to change the way knowledge is created and applied in Life Sciences. He was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for central nervous system (CNS) disorders.